NYMX | Nymox Pharmaceutical Corporation Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.1999 - 0.1999
52 Week Range	0.1700 - 0.7400
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	881,574
Average Volume	134,777
Shares Outstanding	91,265,104
Market Cap	18,243,894
Sector	Healthcare
Industry	Biotechnology
IPO Date	1997-11-26

Valuation
Profitability
Growth
Health
P/E Ratio	-2.86
Forward P/E Ratio	N/A
EPS	-0.07
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	3
Country	Bahamas
Website	NYMX

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas.

NYMX's peers: IMRA

*Chart delayed

Analyzing fundamentals for NYMX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see NYMX Fundamentals page.

Watching at NYMX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on NYMX Technicals page.